Drug Trial Radar · NCT03606174
A Phase 2 Study of Sitravatinib in Combination With PD-(L)1 Checkpoint Inhibitor Regimens in Patients With Advanced or Metastatic Urothelial Carcinoma
Last checked: Nov 19, 2026Latest source record: Aug 24, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
260
Actual
Start
Sep 11, 2018
Primary completion
Aug 3, 2022
Study completion Aug 22, 2022
Sponsor
- Lead sponsor
- Mirati Therapeutics Inc.Bristol Myers Squibb (BMY)
- Sponsor type
- Industry
- First posted
- Jul 30, 2018
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study will evaluate the clinical activity of PD-(L)1 Checkpoint Inhibitor regimens in combination with the investigational agent sitravatinib in patients with advanced or metastatic urothelial carcinoma.
Conditions
- Urothelial Carcinoma
- Urothelial Carcinoma Bladder
- Urothelial Carcinoma Ureter
- Urothelial Carcinoma of the Renal Pelvis and Ureter
- Urothelial Carcinoma Urethra
Interventions
SitravatinibDrug
Sitravatinib is a small molecule inhibitor of receptor tyrosine kinases
NivolumabDrug
Nivolumab is a programmed death receptor-1 (PD-1) blocking antibody
PembrolizumabDrug
Pembrolizumab is a programmed death receptor-1 (PD-1) blocking antibody
Enfortumab vedotinDrug
Enfortumab is a Nectin-4 directed antibody-drug conjugate (ADC) comprised of a monoclonal antibody conjugated to the small molecule microtubule disrupting agent, monomethyl auristatin E (MMAE)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective Response Rate (ORR)Time frame: Up to approximately 3 years
Locations
36 sites in 1 country. Site status is shown where the registry gives one.
The University of Arizona Cancer Center
Tucson, Arizona
University of California Irvine
Irvine, California
Rocky Mountain Cancer Centers
Aurora, Colorado
Yale School of Medicine
New Haven, Connecticut
SCRI - Florida Cancer Specialists- North Region
St. Petersburg, Florida
Moffitt Cancer Center
Tampa, Florida
SCRI - Florida Cancer Specialists - West Palm Beach
West Palm Beach, Florida
The University of Chicago
Chicago, Illinois
Indiana University - Melvin & Bren Simon Cancer Center
Indianapolis, Indiana
Norton Cancer Institute - Broadway
Louisville, Kentucky
Ochsner Cancer Institute
New Orleans, Louisiana
Maryland Oncology Hematology, P.A.
Lanham, Maryland
Dana Farber Cancer Institute
Boston, Massachusetts
Barbara Ann Karmanos Cancer Institute
Detroit, Michigan
Washington University School of Medicine - Siteman Cancer Center
St Louis, Missouri
GU Research Network/Urology Cancer Center
Omaha, Nebraska
Comprehensive Cancer Centers of Nevada - Southwest
Las Vegas, Nevada
New York Oncology Hematology - Albany Medical Center
Albany, New York
Roswell Park Cancer Institute
Buffalo, New York
Northwell Health Monter Cancer Center
Lake Success, New York
NYU Langone Laura & Isaac Perlmutter Cancer Center
New York, New York
Memorial Sloan-Kettering Cancer Center
New York, New York
New York-Presbyterian - Weill Cornell Medical Center
New York, New York
University of North Carolina - Lineberger Comprehensive Cancer Center
Chapel Hill, North Carolina
Duke University Hospital
Durham, North Carolina
The Ohio State University College of Medicine
Columbus, Ohio
Allegheny General Hospital
Pittsburgh, Pennsylvania
Vanderbilt University - Ingram Cancer Center
Nashville, Tennessee
Texas Oncology-Austin Central
Austin, Texas
Texas Oncology- Memorial City
Houston, Texas
University of Texas - MD Anderson Cancer Center
Houston, Texas
University of Texas Health Science Center
San Antonio, Texas
Texas Oncology - Tyler
Tyler, Texas
Virginia Cancer Specialists- Fairfax
Fairfax, Virginia
Virginia Oncology Associates
Norfolk, Virginia
Seattle Cancer Center Alliance
Seattle, Washington
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.